- Home
- RCKT vs SUPN Comparison
RCKT vs SUPN Comparison
Compare RCKT & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- SUPN
- Stock Information
- Founded
- RCKT 1999
- SUPN 2005
- Country
- RCKT United States
- SUPN United States
- Employees
- RCKT N/A
- SUPN 674
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- RCKT Health Care
- SUPN Health Care
- Exchange
- RCKT Nasdaq
- SUPN Nasdaq
- Market Cap
- RCKT 264.0M
- SUPN 1.8B
- IPO Year
- RCKT N/A
- SUPN 2012
- Fundamental
- Price
- RCKT $3.02
- SUPN $32.34
- Analyst Decision
- RCKT Buy
- SUPN Hold
- Analyst Count
- RCKT 13
- SUPN 2
- Target Price
- RCKT $18.50
- SUPN $36.00
- AVG Volume (30 Days)
- RCKT 4.0M
- SUPN 703.8K
- Earning Date
- RCKT 08-04-2025
- SUPN 08-05-2025
- Dividend Yield
- RCKT N/A
- SUPN N/A
- EPS Growth
- RCKT N/A
- SUPN N/A
- EPS
- RCKT N/A
- SUPN 1.11
- Revenue
- RCKT N/A
- SUPN $667,997,000.00
- Revenue This Year
- RCKT N/A
- SUPN N/A
- Revenue Next Year
- RCKT N/A
- SUPN $12.02
- P/E Ratio
- RCKT N/A
- SUPN $28.41
- Revenue Growth
- RCKT N/A
- SUPN 11.82
- 52 Week Low
- RCKT $2.19
- SUPN $25.94
- 52 Week High
- RCKT $26.98
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- RCKT 45.25
- SUPN 53.20
- Support Level
- RCKT $2.76
- SUPN $31.35
- Resistance Level
- RCKT $2.96
- SUPN $32.55
- Average True Range (ATR)
- RCKT 0.20
- SUPN 0.91
- MACD
- RCKT 0.16
- SUPN 0.04
- Stochastic Oscillator
- RCKT 88.57
- SUPN 60.93
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.